The generics are smart enough not to put anything on the label to blatantly cause inducement. They don’t have too. They know the way our insurance and medical system works and they know that having a generic version of V will lead to infringement and doctors and insurance companies will support this obvious infringement if a cheaper generic version of V is available. They are so bold as to list the current market for Vascepa in their JPM slides because they know that is the true market they seek and will infringe upon if they are given a carve out label.
Market Data 
Markets 
AI
